在药物QTORINTM第3阶段取得积极结果后,Palvella治疗药物的库存有所上升,尽管股份被稀释,兴趣也随之增加。 Palvella Therapeutics' stock rose after positive Phase 3 results for its drug QTORIN™, despite share dilution and rising short interest.

在Mizuho对股票进行升级并将其价格目标提高到250美元之后,Palvella Serectrical(PVLA)在市场前贸易中的份额上升,并列举了其第3阶段主要药物QTORINTM3.9%的拉帕米素取得的积极结果。 Palvella Therapeutics (PVLA) shares rose in pre-market trading after Mizuho upgraded the stock and raised its price target to $250, citing positive Phase 3 results for its lead drug QTORIN™ 3.9% rapamycin. 该公司完成了160万股的大规模公开发行,每股125美元,筹集了2亿美元,以延长其现金跑道,尽管这项移动使股票稀释。 The company completed an upsized public offering of 1.6 million shares at $125 each, raising $200 million to extend its cash runway, though the move introduces share dilution. 来自H.C. Wainwright、Chardan和其他人的分析家也更新了股票,提高了投资者的信心。 Analysts from H.C. Wainwright, Chardan, and others also upgraded the stock, boosting investor confidence. 尽管空头持仓增加——167万股，占流通股的17.8%——且内部抛售频繁，该股市值仍为16.7亿美元，市场共识评级为“买入”，目标价为176.44美元。 Despite rising short interest—1.67 million shares, or 17.8% of the float—and insider selling, the stock’s market cap stands at $1.67 billion, with a consensus “Buy” rating and a price target of $176.44.